1. Introduction

Angiography guided percutaneous coronary intervention (PCI) has been a standard imaging modality since 1970s. However, in the presence of the limitations of the existing imaging techniques such as image noise, intensity inhomogeneity, and so on, the complexity of the cardiac dynamics and the lack of unambiguous reference landmarks within the myocardium, it remains challenging to robustly and reliably solve these problems. Intravascular ultrasound (IVUS) improves the accuracy of the assessment of vessel overlap, shortening, and calcification while providing more detailed information on plaque burden, morphology, and calcification distribution. Optical coherence tomography (OCT) is an emerging intracoronary imaging technique following IVUS.

Compared with IVUS, OCT has a very high resolution, and it has attracted attention in the evaluation of vulnerable plaques and guided stent placement, especially in the field of coronary heart disease diagnosis and treatment such as acute coronary syndrome. The overall level of evidence was equivalent to IVUS. In the 2014 ESC/European Cardiac Society Association Guidelines for Cardiovascular Revascularization, OCT’s recommendation for optimizing PCI was upgraded to IVUS-equivalent Class IIa. The ILUMIEN I study published in 2015 showed that preoperative and/or postoperative OCT of PCI can affect the interventional strategy of the surgeon. Recent ILUMIEN II study has shown that OCT is not inferior to IVUS in guiding stent expansion.

Comparison of clinical outcomes between intravascular optical coherence tomography-guided and angiography-guided stent implantation: A meta-analysis of randomized control trials and systematic review

Yu Jiang, MDa∗, Li-Peng He, MDb, Ren Gong, MDc, Guang-Tao Leida, Yan-Qing Wua, PhD

Abstract

Objective: This systematic review was designed to evaluate the overall efficacy of optical coherence tomography (OCT)-guided implantation versus angiography-guided for percutaneous coronary intervention.

Methods: The following electronic databases, such as CENTRAL, PubMed, Cochrane, and EMBASE were searched for systematic reviews to investigate OCT-guided and angiography-guided implantation. We measured the following 7 parameters in each patient: stent thrombosis, cardiovascular death, myocardial infarction, major adverse cardiac events (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), all-cause death.

Results: In all, 11 studies (6 RCTs and 5 observational studies) involving 4026 subjects were included, with 1903 receiving intravascular ultrasound-guided drug-eluting stent (DES) implantation and 2123 using angiography-guided DES implantation. With regard to MACE, MT, TLR, TVR, stent thrombosis and all-cause death, the group of OCT-guided implantation had no significant statistical association with remarkably improved clinical outcomes. However, its effect on cardiovascular death has a significant statistical difference in angiography-guided implantation group.

Conclusion: In the present pool analysis, OCT-guided DES implantation showed a tendency toward improved clinical outcomes compared to angiography-guided implantation. More eligible randomized clinical trials are warranted to verify the findings and to determine the beneficial effect of OCT-guidance for patients.

Abbreviations: MACE = major adverse cardiac events, MI = myocardial infarction, OCT = optical coherence tomography, PCI = percutaneous coronary intervention, TLR = target lesion revascularization, TSA = trial sequential analysis, TVR = target vessel revascularization.

Keywords: angiography, meta-analysis, optical coherence tomography, percutaneous coronary intervention

*Correspondence: Yu Jiang, Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, Jiangxi 330006, China (e-mail: 3494106@qq.com).

Received: 29 October 2018 / Received in final form: 7 January 2019 / Accepted: 9 January 2019

http://dx.doi.org/10.1097/MD.0000000000014300
OCT is the highest resolution intraluminal imaging technology at present and able to more accurately detect subtle stent morphologies with a resolution 10 times that of IVUS. However, recently, the evidence demonstrating the clinical usefulness of OCT are inadequate for sufficiently powered randomized clinical trials. We, therefore, performed a systematic review and meta-analysis of all available trials to investigate the efficacy and safety routine OCT-guided PCI.

2. Materials and methods

2.1. Ethical approval

Ethics approval was waived because this study does not involve any human participants or animals.

2.2. Search strategy

We performed the current meta-analysis based on the Cochrane Handbook for Systematic Reviews of Interventions and Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. We conducted a systematic screening process using the CENTRAL, PubMed, EMBASE, and Cochrane Database of Systematic Reviews from their inception to March 2018, based on the MeSH terms and free keywords: “percutaneous coronary intervention; “OCT;” “optical coherence tomography;” “optical frequency domain; “OFDI.” All relevant publications were identified without language restrictions; in which we identified full-text papers from reference materials for further evaluation.

2.3. Inclusion criteria

Articles that were related to the following inclusion criteria were included in this analysis:

1. patients underwent PCI using a metallic drug-eluting stent (DES);
2. trails focused on comparing OCT-guided implantation and angiography-guided or IVUS-guided implantation;
3. more than 1 of the following parameters were mentioned in studies: stent thrombosis, cardiovascular death, myocardial infarction (MI), major adverse cardiac events (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), all-cause death;
4. randomized controlled trials (RCTs), observational studies.

Studies should be excluded with the following exclusion criteria:

1. trials without control group;
2. the reported data was clearly erroneous or incomplete, and were unable to provide research outcomes;
3. duplicated previous publications.

2.4. Risk-of-bias assessments

The risk of bias was evaluated in each mentioned studies based on Cochrane handbook version 5.1.0 for Systematic Reviews by Cochrane Collaboration. Study quality was evaluated including allocation concealment, blinding of outcome assessment, blinding of participants and personnel, incomplete outcome data, random sequence generation, selective reporting, and other biases. Each entry was then classified as “high risk,” “unclear risk,” and “low risk.”

2.5. Data selection and extraction

After screening process, studies were then assigned to certain topic(s). Using Thomson Research Software (EndNote X4), we extracted relevant data for accuracy assessment. Any unclear information should be with more details of original articles. “excluded (reason),” “pending,” and “included” were involved into the “notes” column. We should retract “pending” articles from the references.

A self-designed data extraction form was used to independently extract contents by 2 researchers including lead author, year of publication, study design, participant characteristics, outcomes measures, and follow-up time. The literature screening process, data extraction, and quality evaluation process were performed separately by 2 reviewers. In case of disagreement, a third investigator would be involved to help resolve the disagreement through discussion.

2.6. Statistical analysis

The Cochrane Collaborations have offered Review Manager Software (RevMan5.3) for statistical analysis. Odds ratios (OR) and its 95% confidence interval (CI) were utilized for binary data and effect size in the meta-analysis. The chi-square was used to assess the significance of heterogeneity, and the degree of heterogeneity was then examined through the I² statistic. Fixed-effect model was used if the assessment of heterogeneity was insignificant (I² < 50%). If the source of heterogeneity was uncertain, we used the random-effect model for further analysis.

2.7. Trial sequential analysis

Trial sequential analysis (TSA) is a method for estimating sample size, which can adjust random errors and calculate the sample size, through the TSA 0.9 Beta (available at http://www.ctu.dk/tsa). We estimated a diversity-adjusted required information size, which was consisted of type power = 80%, I error α = 5%, as well as 2-sided testing. Hypothesis was that 25% and 50% relative reduction could be obtained through OCT guidance in the risk of MACE and stent thrombosis, and in the angiography-guided group, there was 10% anticipated event rate for MACE and 1.5% for stent thrombosis. A graph of the cumulative Z curve presented the major results, and the boundaries in this graph were then determined by the O’Brien-Fleming α-spending function for final non-inferiority, inferiority, or superiority.

3. Results

3.1. Study selection process

A total of 735 articles were retrieved. After 76 duplicates were deleted from the total amount of articles, 626 irrelevant citations were excluded based on the review of titles and abstracts. Intensive reading full-text review of the 33 included articles, 22 articles were further eliminated. Finally, a total of 11 studies published between 2015 and 2018 were assessed for eligibility in the meta-analysis (Fig. 1).

3.2. Quality assessment

There were 11 studies reference to random sequence generation used web-based system or random table, while 1 study was just reported as randomized trials and without randomization description; 5 studies of random
grouping method were assessed as a high risk of bias. 4 trials described allocate patients by sealed opaque envelopes. Because the nature of interventions, it was not possible to blind the operator, investigator, or patient for the allocated implantation technique in all trials, but the operator was blinded to the postprocedure OCT images in 1 trail. Most trials had comparable baselines clinical characteristics except that 1 trial was statistically significant difference when comparing the 2 groups for hypertension. Blinding of outcome assessment was independent in most studies except to 2 trails. None of the included studies had a selective report nor incomplete report. In all, 3 studies were with high methodological quality, 3 studies with moderate quality and the rest 5 studies with low quality. Figure 2 and Figure 3 presented a summary of the quality assessment process.

3.3. Characteristics of study selection

Totally, 4026 selective patients were included in this meta-analysis, 1903 receiving OCT-guided DES implantation, 2123 using angiography-guided DES implantation. Studies included patients with coronary heart disease, acute coronary syndromes, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction. Among those patients, follow-up period varied from 30 days to 12 months, sample sizes from 69 to 817, and mean ages from 50 to 80 years. No significant statistical difference was observed when comparing the 2 groups for baseline clinical characteristics such as diabetes and smoker. Hypertension was found significant statistical difference in 1 trail. Intervention strategies were similar among most of the trials. The major characteristics of included studies are depicted in Table 1.

4. Outcomes and synthesis of results

4.1. MACE

Eight studies reported MACE, included a total of 2413 patients (1197 in OCT-guided PCI group and 1216 in angiography-guided PCI group). There was no statistical
between-study heterogeneity in OR of studies ($P = .46, I^2 = 0\%$), we used a fixed effect model for merging. As displayed in Figure 4, pooled estimates of effect sizes showed no significant statistical difference of MACE when comparing the 2 groups (OR $= 0.72$, 95% CI [0.50, 1.03], $P = .07$).

### 4.2. Stent thrombosis

Nine studies$^{[10,11,13,15–20]}$ reported stent thrombosis, included a total of 3682 patients (1724 in OCT-guided PCI group and 1958 in angiography-guided PCI group). There was no statistical between-study heterogeneity in OR of studies ($P = .52, I^2 = 0\%$), a fixed effect model was used for merging. As displayed in Figure 5, pooled estimates of effect sizes showed no significant statistical difference of stent thrombosis when comparing 2 groups (OR $= 0.53$, 95% CI [0.25, 1.12], $P = .09$).

### 4.3. MI

Nine studies$^{[10,13–20]}$ reported MI including a total of 3798 patients (1789 in OCT-guided PCI group and 2009 in angiography-guided PCI group). There was no statistical between-study heterogeneity in OR of studies ($P = .83, I^2 = 0\%$), a fixed effect model was used for merging. As displayed in Figure 6, pooled estimates of effect sizes showed no significant statistical difference of MI when comparing 2 groups (OR $= 0.80$, 95% CI [0.55, 1.18], $P = .26$).

### 4.4. TLR and TVR

Five studies$^{[10,13–15,18]}$ reported TLR, included a total of 1432 patients (709 in OCT-guided PCI group and 723 in angiography-guided PCI group). Six studies$^{[13,16–20]}$ reported TVR, included a total of 3009 patients (1404 in OCT-guided PCI group and 1605 in angiography-guided PCI group). There was no statistical between-study heterogeneity in OR of studies (TLR: $P = .16, I^2 = 40\%$; TVR: $P = .31, I^2 = 17\%$), fixed effect model was used for merging. As displayed in Figure 7, pooled estimates of effect sizes showed no significant statistical difference of TLR, TVR when comparing 2 groups (TLR: OR $= 0.49$, 95% CI [0.21, 1.11], $P = .09$; TVR: OR $= 0.71$, 95% CI [0.44, 1.13], $P = .15$).

### 4.5. All-cause death and cardiovascular death

Five studies$^{[10,13,14,17,19]}$ reported all-cause death, cardiovascular death, included a total of 1949 patients (988 in OCT-guided PCI group and 961 in angiography-guided PCI group). Six studies$^{[11,15,16,18–20]}$ reported cardiovascular death, included a total of 2604 patients (1176 in OCT-guided PCI group and 1428 in angiography-guided PCI group). We utilized a fixed effect model for merging. As displayed in Figure 8, pooled estimates of effect sizes showed no significant statistical difference of all-cause death (OR $= 0.59$, 95% CI [0.33, 1.04], $P = .07$), significant statistical difference of cardiovascular death when comparing 2 groups (OR $= 0.38$, 95% CI [0.19, 0.74], $P = .005$).

### 4.6. Sensitivity analysis

By omitting 1 study at a time, the sensitivity analysis was conducted (Table 2). With regarding to MACE, the pooled results altered obviously when omitting the study of Ali et al$^{[10]}$ or Kala et al$^{[14]}$ Notably, significantly improved result was found after omitting these 2 studies. On the other hand, for stent thrombosis, the pooled result altered remarkably in the absence of the study of Sheth et al$^{[20]}$ significantly improved result was found after omitting this study.

### 4.7. TSA

The evaluation of MACE though TSA indicated that the cumulative Z curve did not cross the trial sequential monitoring boundaries for superiority, and only 18.8% (1504 patients) of required information size (7983 patients) was accrued. For the assessment of stent thrombosis, only 21.0% (1303 patients) of required information size (6209 patients) was accrued. The Z curve did not cross any monitoring boundaries. The TSA results indicate that inadequate power for making a clear conclusion upon MACE and stent thrombosis these 2 endpoints. As displayed in Figures 9 and 10.
5. Discussion

Our meta-analysis of 6 RCTs and 5 observational studies comprising a total of 4026 patients, showed that OCT-guided DES implantation was not significantly associated with a lower incidence of MACE, MT, TLR, TVR, stent thrombosis and all-cause death, while only significantly associated with a lower incidence of cardiovascular death. In present pool analysis, OCT-guided DES implantation showed a tendency toward improved clinical outcomes compared to angiography-guided implantation.

The preoperative PCI OCT test can accurately assess pre-treated lesions and help the surgeon select the appropriate stent and the location of the stent release. At the same time, OCT can provide the lumen and diameter of the reference vessel, which would be an excellent parameter with potential to be evaluated in future studies for the surgeon to determine prognostic implications. According to the size of the reference blood vessel, a safe postdilation balloon is selected to prevent insufflation. In addition, OCT imaging before PCI can evaluate plaque morphology and predict the outcome after PCI. The OCT test after PCI can accurately evaluate stent expansion, stent adherence, stent prolapse, stent edge dissection, and stent thrombosis, providing surgeons with more anatomical information and helping surgeons optimize PCI strategy.

Preoperative OCT examination can accurately measure the degree of stenosis, length of lesions, plaque distribution, and nature of the main branch and branch opening, which helps the surgeon to choose the right one interventional device and branch stent treatment strategy. The real-time 3D imaging capabilities of the new generation of OCT systems can also provide the spatial distribution and structure of blood vessels, especially for the display of bifurcation openings. Studies have shown that 3D-OCT guidance for bifurcation stent placement is feasible and can reduce stent malapposition. Therefore, OCT can be considered when clinically guiding treatment of bifurcation lesions.

Pathological control studies have shown that the sensitivity (95–96%) and specificity (97%) of the calcification lesions detected by OCT are high. Accurate detection of preoperative calcified lesions is critical for the choice of revascularization. OCT imaging technology has obvious advantages in the field of absorbable stents. The current average thickness of bioresorbable stents is relatively large (114–228 μm), and compared with metal stents, bioresorbable materials are harder and less malleable. Absorbable stents are well-prepared to respond to lesions and are accurate. Vascular diameter and lesion characteristics are measured to select the appropriate size of the absorbable stent. Therefore, compared with angiography-guided implantation, OCT is an extremely necessary influencing tool for the selection of the correct size of the stent and the process of guiding PCI. In addition, in addition, OCT has unique advantages for the follow-up evaluation of bioresorbable stents.

Our meta-analysis showed that OCT-guided PCI may be numerically reduced cardiac death compare to angiography-guided PCI, while statistical significance was not attained for MACE and the remaining 5 outcomes. Sensitivity analysis found that the pooled estimate of MACE altered obviously after excluding the ILUMIEN III study (OR 0.60, 95% CI 0.45–0.80, P = .005) and the study of Kala et al (OR 0.60, 95% CI 0.45–0.80, P = .005). Similarly, the pooled estimate of stent thrombosis altered remarkably in the absence of the study of Sheth et al (OR 0.60, 95% CI 0.45–0.80, P = .005). A
| Author, yr | Study design | Procedures | Gender M/F | Mean age | Diabetes (%) | Hypertension (%) | Smoker (%) | Treated lesion | Outcome measures | Follow-up |
|------------|--------------|------------|------------|----------|--------------|-----------------|------------|----------------|-----------------|-----------|
| Ali, 2016  | RCT/multicenter | OCT       | 109/49     | 66 (59–72) | 33%          | 78%             | 18%        | Coronary heart disease | 1 2 3 4 5 7 | 30 d     |
| Antonsen, 2015 | RCT/single centre | Angiography | 107/39     | 67 (56–74) | 29%          | 75%             | 24%        | NSTEMI | 1 2 6 | 6 mo   |
| Hansheer, 2018 | Observational/single centre | OCT | 34/16      | 62.6 (11.5) | 10%          | 56%             | 36%        | NSTEMI | 1 | 3 mo   |
| Iannaccone, 2016 | Observational/multicenter | OCT | 29/7       | 56.4 (11.5) | 36.1%        | 69.4%           | 44.4%      | Coronary artery disease | 1 | 7 mo   |
| Kala, 2018 | RCT/multicenter | OCT       | 83/22      | 61.2 (10.4) | 17%          | 47%             | 58%        | STEMI | 1 3 4 7 | 9 mo   |
| Kim, 2016  | RCT/multicenter | OCT       | 87/9       | 60 (13)     | 17%          | 52%             | 59%        | STEMI | 1 3 4 6 | 12 mo  |
| Kubo, 2017 | RCT/multicenter | OCT       | 315/97     | 60.8 (11.9) | 21.7%        | 55.8%           | 39.2%      | Coronary artery disease | 1 2 3 5 6 | 12 mo  |
| Meneveau, 2016 | RCT/multicenter | OCT | 122/46     | 63.0 (10.3) | 38.1%        | 46.4%           | 59.5%      | NSTE-ACS | 2 3 5 7 | 6 mo   |
| Otake, 2018 | RCT/multicenter | OCT       | 91/29      | 60.2 (11.3) | 15.8%        | 41.7%           | 42.5%      | Coronary artery disease | 1 2 3 4 5 6 | 12 mo  |
| Prati, 2012 | Observational/multicenter | Angiography | 89/7     | 68 (13)     | 73.5%        | 46.9%           | 20.4%      | Coronary artery disease | 2 3 5 6 7 | 12 mo  |
| Sheth, 2016 | Observational/multicenter | OCT | 273/82     | 67.0 (11.9) | 73.8%        | 29.0%           | 33.7%      | STEMI | 2 3 5 6 | 12 mo  |

NR = not report, NSTE-ACS = non–ST-segment elevation acute coronary syndromes, NSTEMI = non–ST-segment elevation myocardial infarction, STEMI = ST-segment elevation myocardial infarction.

Outcome measures: (1) major adverse cardiac events; (2) stent thrombosis; (3) myocardial infarction; (4) target lesion revascularization; (5) target vessel revascularization; (6) cardiovascular death; (7) all-cause death.
Figure 4. Comparison of major adverse cardiac events between OCT-guided group and angiography-guided group. OCT = optical coherence tomography.

Figure 5. Comparison of stent thrombosis between OCT-guided group and angiography-guided group. OCT = optical coherence tomography.

Figure 6. Comparison of myocardial infarction between OCT-guided group and angiography-guided group. OCT = optical coherence tomography.
Figure 7. Comparison of target lesion revascularization and target vessel revascularization between OCT-guided group and angiography-guided group. OCT = optical coherence tomography.

Figure 8. Comparison of cardiovascular death and all cause death between OCT-guided group and angiography-guided group. OCT = optical coherence tomography.
A possible explanation for the divergence may be the inconsistency of the duration of follow-up time. For instance, the follow-up time of ILUMIEN III study\cite{10} was 30 days, it was too short to observe the expected outcomes. Noteworthy, the findings of our study should be cautiously interpreted, because the pool analysis included both randomized trials and observational studies which may entail some residual confounding. The present work enrolled 6 recent RCTs, TSA results indicate that inadequate power for making a clear conclusion upon MACE and stent thrombosis these 2 endpoints, which reflects more adequately powered randomized trials are required.

Table 2

| Omitting study | MACE (fixed model) OR (95% CI), $P$ heterogeneity, $I^2$, $n$ | stent thrombosis (fixed model) $OR$ (95% CI) |
|----------------|---------------------------------------------|---------------------------------|
| Ali, 2016      | 0.68 (0.47–0.98), .60, 0%, 2238            | 0.47 (0.21–1.04), .49, 0%, 3410 |
| Antonsen, 2015 | 0.74 (0.51–1.06), .42, 1%, 2460            | 0.54 (0.25–1.17), .42, 0%, 3623 |
| Hamshere, 2018 | 0.76 (0.53–1.10), .48, 0%, 2459            |                                  |
| Iannaccone, 2016| 0.72 (0.43–1.20), .35, 10%, 1935          | 0.79 (0.35–1.82), .81, 0%, 3162 |
| Kala, 2018     | 0.69 (0.48–1.00), .50, 0%, 2342            |                                  |
| Kim, 2016      | 0.74 (0.51–1.07), .36, 9%, 2296            | 0.55 (0.25–1.21), .45, 0%, 3417 |
| Kubo, 2017     | 0.69 (0.46–1.04), .37, 8%, 1704            | 0.53 (0.24–1.17), .41, 2%, 2689 |
| Meneveau, 2016 |                                  | 0.55 (0.25–1.12), .52, 0%, 3469 |
| Otake, 2018    | 0.75 (0.52–1.08), .51, 0%, 2441            | 0.54 (0.25–1.18), .43, 0%, 3605 |
| Prati, 2012    |                                  | 0.53 (0.24–1.17), .41, 2%, 3036 |
| Sheth, 2016    |                                  | 0.53 (0.25–1.12), .52, 0%, 3709 |

CI = confidence interval, MACE = major adverse cardiac events, $n$ = sample size, OR = odds ratio.
Author contributions

Conceptualization: Yu Jiang, Yan-Qing Wu.
Data curation: Li-Peng He, Ren Gong, Guang-Tao Lei.
Formal analysis: Li-Peng He, Ren Gong, Guang-Tao Lei.
Writing – original draft: Yu Jiang, Yan-Qing Wu.
Writing – review and editing: Yan-Qing Wu.

References

[1] Zhang H, Gao Z, Xu L, et al. A meshfree representation for cardiac medical image computing. IEEE J Trans Eng Health Med 2018;6:1800212.
[2] Hibi K, Kimura K, Umemura S. Clinical utility and significance of intravascular ultrasound and optical coherence tomography in guiding percutaneous coronary interventions. Circ J 2015;79:24–33.
[3] Montalescot G, Sechtem U, Achenbach S, et al. Task Force Members 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949–3003.
[4] Windecker S, Kolh P, Alfonso F, et al. Authors/Task Force Members 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2341–619.
[5] Wijns W, Shire J, Jones MR, et al. Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study. Eur Heart J 2015;36:3346–55.
[6] Machara A, Ben-Yehuda O, Ali Z, et al. Comparison of stent expansion guided by optical coherence tomography versus intravascular ultrasound: the ILUMIEN II study (observational study of optical coherence tomography [OCT] in patients undergoing fractional flow reserve [FFR] and percutaneous coronary intervention). JACC Cardiovasc Interv 2013;6:1794–14.
[7] Gutierrez-Chico JL, Alegria-Barrero E, Teijeiro-Mestre R, et al. Optical coherence tomography: from research to practice. Eur Heart J Cardiovas Imaging 2012;13:370–84.
[8] Higgins J, Green SE. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration (Eds). Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie. John Wiley & Sons Ltd, Chichester, England 2011. 5, 538.
[9] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
[10] Ali ZA, Machara A, Genereux P, et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. Lancet 2016;388:2618–28.
[11] Antonsen L, Thayssen P, Machara A, et al. Optical coherence tomography guided percutaneous coronary intervention with nobori stent implantation in patients with non-ST-segment-elevation myocardial infarction (OCTACS) trial: difference in strut coverage and dynamic malapposition patterns at 6 months. Circ Cardiovasc Interv 2015;8:e002446.
[12] Hamshere S, Byrne A, Guttmann O, et al. An observational study of clinical outcomes of everolimus-eluting bioresorbable scaffolds comparing the procedural use of optical coherence tomography against angiography alone. Coron Artery Dis 2018;29:482–8.

Figure 10. Trial sequential analyses for stent thrombosis.
[13] Iannaccone M, D’Ascenzo F, Frangieh AH, et al. Impact of an optical coherence tomography guided approach in acute coronary syndromes: a propensity matched analysis from the international FORMIDABLE-CARDIOGROUP IV and USZ registry. Catheter Cardiovasc Interv 2017;90:E46–52.

[14] Kala P, Cervinka P, Jakl M, et al. OCT guidance during stent implantation in primary PCI: a randomized multicenter study with nine months of optical coherence tomography follow-up. Int J Cardiol 2018;250:98–103.

[15] Kim IC, Yoon HJ, Shin ES, et al. Usefulness of frequency domain optical coherence tomography compared with intravascular ultrasound as a guidance for percutaneous coronary intervention. J Interv Cardiol 2016;29:216–24.

[16] Kubo T, Shinke T, Okamura T, et al. Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one-year angiographic and clinical results. Eur Heart J 2017;38:3139–47.

[17] Meneveau N, Souteyrand G, Motreff P, et al. Optical coherence tomography to optimize results of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome: results of the multicenter, randomized DOCTORS study (does optical coherence tomography optimize results of stenting). Circulation 2016;134:906–17.

[18] Otake H, Kubo T, Takahashi H, et al. Optical frequency domain imaging versus intravascular ultrasound in percutaneous coronary intervention (OPINION trial): results from the OPINION imaging study. JACC Cardiovasc Imaging 2018;11:111–23.

[19] Prati F, Di Vito L, Biondi-Zoccai G, et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l’Infarto-optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. EuroIntervention 2012;8:823–9.

[20] Sheth TN, Kajander OA, Lavi S, et al. Optical coherence tomography-guided percutaneous coronary intervention in ST-segment-elevation myocardial infarction: a prospective propensity-matched cohort of the thrombectomy versus percutaneous coronary intervention alone trial. Circ Cardiovasc Interv 2016;9:e003414.

[21] Xu L, Huang X, Ma J, et al. Value of three-dimensional strain parameters for predicting left ventricular remodeling after ST-elevation myocardial infarction. Int J Cardiovasc Imaging 2017;33:663–73.

[22] Wu D, Li C, Chen Y, et al. Influence of blood pressure variability on early carotid atherosclerosis in hypertension with and without diabetes. Medicine 2016;95:e3864.

[23] Ino Y, Kubo T, Matsuo Y, et al. Optical coherence tomography predictors for edge restenosis after everolimus-eluting stent implantation. Circ Cardiovasc Interv 2016;9.

[24] Sawlani NN, Bhatt DL. How to decipher OCT after PCI. JACC Cardiovasc Imaging 2015;8:1306–8.

[25] Kranasos A, Tu S, van Ditzhuijzen NS, et al. A novel method to assess coronary artery bifurcations by OCT: cut-plane analysis for side-branch ostial assessment from a main-vessel pullback. Eur Heart J Cardiovasc Imaging 2015;16:177–89.

[26] Jia H, Hu S, Uemura S, et al. Insights into the spatial distribution of lipid-rich plaques in relation to coronary artery bifurcations: an in vivo optical coherence tomography study. Coron Artery Dis 2015:26:133–41.

[27] Kubo T, Akasaka T, Shite J, et al. OCT compared with IVUS in a coronary lesion assessment: the OPUS-CLASS study. JACC Cardiovasc Imaging 2013;6:1095–104.

[28] Tanaka A, Imanishi T, Kitabata H, et al. Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. Eur Heart J 2009;30:1348–55.

[29] Gao R, Yang Y, Han Y, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol 2015;66:2298–309.

[30] Gomez-Lara J, Diletti R, Brugaletta S, et al. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study. EuroIntervention 2012;8:214–24.